Evidence map›Paper›PMID 29563154›Full record

ArticleThe Journal of biological chemistry2018

Expression of human monolysocardiolipin acyltransferase-1 improves mitochondrial function in Barth syndrome lymphoblasts.

Edgard M Mejia, Hana Zegallai, Eric D Bouchard, Versha Banerji, Amir Ravandi, Grant M Hatch

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Barth syndrome: mechanisms and management.The application of clinical genetics · 2019
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Edgard M MejiaFrom the Department of Pharmacology and Therapeutics and.
Hana ZegallaiFrom the Department of Pharmacology and Therapeutics and.
Eric D BouchardResearch Institute in Oncology and Hematology, Cancer Care Manitoba, Winnipeg, Manitoba R3E 0V9, Canada.
Versha BanerjiResearch Institute in Oncology and Hematology, Cancer Care Manitoba, Winnipeg, Manitoba R3E 0V9, Canada.
Amir RavandiInstitute of Cardiovascular Sciences, St. Boniface Hospital Research Center, Winnipeg, Manitoba R2H 2A6, Canada, and.
Grant M HatchFrom the Department of Pharmacology and Therapeutics and ghatch@chrim.ca.
University of Manitoba · CACancerCare Manitoba · CAChildren's Hospital Research Institute of Manitoba · CAResearch Institute in Oncology and Hematology · CASt. Boniface Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mitochondrial polyglycerophospholipid cardiolipin (CL) is remodeled to obtain specific fatty acyl chains. This is predominantly accomplished by the transacylase enzyme tafazzin (TAZ). Barth syndrome (BTHS) patients with

Indexed as

AcyltransferasesBarth SyndromeCardiolipinsCase-Control StudiesCells, CulturedFatty AcidsHumansLymphocytesLysophospholipidsMitochondriaMutationAcyltransferasesCardiolipinsFatty AcidsLysophospholipidsmonolysocardiolipin acyltransferasecardiolipingenetic diseaselipid metabolismmitochondrial diseasephospholipid metabolism

Identifiers

PMID29563154
PMCPMC5961033
OpenAlexW2794091248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.